Cosciens Biopharma Files 6-K Report
Ticker: CSCIF · Form: 6-K · Filed: Dec 23, 2024 · CIK: 1113423
Sentiment: neutral
Topics: sec-filing, 6-k, biopharma
TL;DR
Cosciens Biopharma (fka Aeterna Zentaris) filed a standard 6-K report on Dec 23, 2024.
AI Summary
Cosciens Biopharma Inc. (formerly Aeterna Zentaris Inc.) filed a Form 6-K on December 23, 2024. The filing is a report of a foreign private issuer for the month of December 2024. The company is incorporated in A6 and its fiscal year ends on December 31st. Its principal executive offices are located in Toronto, Ontario, Canada.
Why It Matters
This filing provides routine updates for foreign private issuers, ensuring compliance with SEC regulations for companies like Cosciens Biopharma Inc. that are listed in the US but incorporated elsewhere.
Risk Assessment
Risk Level: low — This filing is a routine report and does not contain significant new financial or operational information that would immediately impact risk.
Key Players & Entities
- COSCIENS Biopharma Inc. (company) — Filer
- Aeterna Zentaris Inc. (company) — Former company name
- Norton Rose Fulbright Canada, LLP (company) — Legal counsel/address provider
- 20241223 (date) — Filing date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, providing information that the issuer makes or is required to make public in its home country.
What was the previous name of COSCIENS Biopharma Inc.?
The previous name of COSCIENS Biopharma Inc. was Aeterna Zentaris Inc., with a name change date of June 17, 2004.
Where are COSCIENS Biopharma Inc.'s principal executive offices located?
The principal executive offices of COSCIENS Biopharma Inc. are located at c/o Norton Rose Fulbright Canada, LLP, 222 Bay Street, Suite 3000, PO Box 53, Toronto ON M5K 1E7.
What is the SIC code for COSCIENS Biopharma Inc.?
The Standard Industrial Classification (SIC) code for COSCIENS Biopharma Inc. is 2834, which corresponds to Pharmaceutical Preparations.
When does COSCIENS Biopharma Inc.'s fiscal year end?
COSCIENS Biopharma Inc.'s fiscal year ends on December 31st.
Filing Stats: 857 words · 3 min read · ~3 pages · Grade level 15.8 · Accepted 2024-12-23 07:45:22
Filing Documents
- form6-k.htm (6-K) — 31KB
- ex99-1.htm (EX-99.1) — 34KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001493152-24-051206.txt ( ) — 71KB
forward-looking statements
forward-looking statements. Forward-looking synergies as well as the assets, cost structure, financial position, cash flows and growth prospects of the combined company. Risks and factors that could cause actual results or outcomes to differ materially from expectations include, among others, the following: the Company’s patented technologies and value-driving products, and development thereof; the extraction, production and commercialization of active ingredients from natural sources and our ability to successfully market related products; the successful development and marketing of our oat-based pipeline products, including oat-beta glucan, avenanthramides and beta glucan from yeast, as well as such products’ capability to address unmet needs within the nutraceuticals markets; Macrilen® (macimorelin) and the Company’s plans in respect of same, including commercialization and clinical programs as well as in respect of the top line data from the DETECT-trial; the Company’s business strategy; the strategic decision to sunset the Company’s Amyotrophic Lateral Sclerosis (ALS) program; the Company’s positioning in its target markets; the Company’s ability to accelerate the scale-up of PGX Technology towards commercial levels; expectations for completion of the Company’s Edmonton facility and Natex Termitz facility; pre-clinical and clinical studies and trials and their expected timing and results, including the potential to bring certain products to market following such studies and trials; the ability of our pharmaceutical therapeutic assets to address unmet medical needs across a number of indications; management’s assumptions, estimates and judgements; liquidity and capital resources; adequacy of our financial resources to finance operations and e